RecruitingNCT05596253

Incidence and Predictors of Post-TIPS Heart Failure in Patients With Cirrhosis

Incidence and Predictors of Post-TIPS (Transjugular Intrahepatic Portosystemic Shunt (TIPS) Heart Failure in Patients With Cirrhosis


Sponsor

West China Hospital

Enrollment

200 participants

Start Date

Oct 11, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to conduct a prospective trial to investigate the incidence of heart failure in cirrhosis patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the the predictors and modififications of cardiac function.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at what happens to the heart after a procedure called TIPS — a shunt placed in the liver to relieve pressure caused by cirrhosis (severe liver scarring). Researchers want to understand how often heart failure develops after TIPS and what factors make it more likely. **You may be eligible if...** - You have cirrhosis (severe liver scarring) - You recently had a TIPS procedure placed successfully - You are willing to participate **You may NOT be eligible if...** - You have portal hypertension from a cause other than cirrhosis - You have had a previous TIPS or a surgical shunt - You have moderate to severe pulmonary hypertension (high blood pressure in the lungs) - You already have heart failure - You are on dialysis for kidney failure - You have respiratory failure - You have a cancer with a life expectancy of less than 6 months Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETIPS

TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.


Locations(1)

West China Hospital of Sichuan University

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05596253


Related Trials